Innovent Biologics (suzhou) Co. Ltd.
Clinical trials sponsored by Innovent Biologics (suzhou) Co. Ltd., explained in plain language.
-
New drug combo targets tough stomach and pancreatic cancers
Disease control Not yet recruitingThis study is testing a new drug combination called IBI343 for people with advanced stomach or pancreatic cancer that has a specific marker called CLDN18.2. The main goals are to see if the treatment is safe and if it helps shrink tumors. It will enroll about 389 adults who have …
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for lung cancer patients when First-Line drug fails
Disease control Not yet recruitingThis study aims to gather real-world information on how well the drug taletrectinib works and how safe it is for people with advanced ROS1-positive non-small cell lung cancer. It focuses on patients whose cancer has continued to grow despite treatment with another targeted drug c…
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New shot aims to zap bad cholesterol
Disease control Not yet recruitingThis study is testing a new injectable drug called IBI306 to see if it safely lowers 'bad' LDL cholesterol in adults with high cholesterol and mixed lipid levels. About 198 participants will be randomly assigned to receive either the real drug or a placebo (dummy) injection for 1…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Could a shot every few months control your blood pressure?
Disease control Not yet recruitingThis study is testing a new long-acting injectable medication called IBI3016 for people with mild to moderate high blood pressure. About 352 participants will receive either the drug or a placebo as an injection under the skin every 3 or 6 months for up to 2 years. The main goal …
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New Three-Drug attack on stomach cancer tested in surgery patients
Disease control Not yet recruitingThis study is testing whether adding a new drug called IBI343 to a standard treatment helps people with advanced stomach or gastroesophageal cancer. The goal is to shrink the tumor before surgery and prevent it from coming back afterward. It is for patients whose tumors have a sp…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New eye bulging treatment tested against standard care
Disease control Not yet recruitingThis study aims to see if a new drug called teprotumumab N01 works better than standard steroid treatment for controlling active Thyroid Eye Disease. About 92 adults with moderate-to-severe, recently active disease will be randomly assigned to receive either the new drug or the s…
Phase: PHASE4 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New drug trial aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study is testing a drug called IBI363 given to patients before they have surgery to remove stage II or III non-small cell lung cancer. The goal is to see if the drug safely shrinks the tumor, making surgery more effective and potentially preventing the cancer from coming bac…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
First human tests begin for new drug candidate
Knowledge-focused Not yet recruitingThis is a very early study to check the safety of a new drug called IBI3033 and see how it moves through the body. It will involve 8 healthy volunteers who will receive the drug or a placebo. The main goal is to find out if the drug is safe and well-tolerated, not to treat any di…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
First human test for new drug begins
Knowledge-focused Not yet recruitingThis is a very early study to see if a new drug called IBI3033 is safe for people and how it moves through the body. It will involve 32 healthy adults who will receive either the drug or a placebo (a dummy treatment). The main goal is to check for any side effects and measure the…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC